Dr Lal Pathlabs
Dr Lal Pathlabs Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects patient volume growth to be around 4.5%-5%, with efforts to improve this further through new infrastructure and network expansion. The company aims to improve patient volume growth from the current ~4.4%-4.5% towards a higher range, targeting a return to pre-COVID volume growth levels of around 7%-8%.
From Dr Lal Pathlabs's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- The company expects patient volume growth to be around 4.5%-5%, with efforts to improve this further through new infrastructure and network expansion.
- Sample volume grew 9.5% over nine months, with aspirations to accelerate volume growth and potentially reach low double-digit growth in sample volumes with expansion in metro and Tier-1 markets.
- Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities.
- Growth strategy includes expanding lab and collection centers in Tier-2 and Tier-3 towns, and strengthening presence in metros and Tier-1 cities.
- The management aims to improve volume growth back to pre-COVID levels (7%-8% CAGR) while maintaining or improving test per patient.
2 more points from Dr Lal Pathlabs's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Dr Lal Pathlabs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex of around Rs. 30 crore done in first nine months of FY25.
- Plan to open 15-16 new labs in H2 FY25, mainly in Q3 and Q4.
- Ongoing maintenance capex guidance of Rs. 60-70 crore per year, excluding major investments.
- Focus on expanding lab infrastructure in metro and Tier-1 cities.
- Investment also planned in marketing infrastructure alongside labs.
- Organic infrastructure addition includes hiring about 100 people in sales and marketing.
- No major new investments beyond lab expansion and maintenance indicated currently.
2 more points from Dr Lal Pathlabs's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Lal Pathlabs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Dr Lal Pathlabs's call on order book
Pro opens every point from 15K+ earnings calls
Dr Lal Pathlabs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Lal Pathlabs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio DX Ltd (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Thyrocare Technologies Ltd (Q3 FY25)
Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…
Arthneeti Pro · Annual
Dr Lal Pathlabs and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Lal Pathlabs Q3 FY25 results?
The company expects patient volume growth to be around 4.5%-5%, with efforts to improve this further through new infrastructure and network expansion. The company aims to improve patient volume growth from the current ~4.4%-4.5% towards a higher range, targeting a return to pre-COVID volume growth levels of around 7%-8%.
What is Dr Lal Pathlabs share price analysis?
Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs planning capital expenditure?
Capex of around Rs.
Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.